Access cutting-edge ocular myasthenia gravis treatment through this clinical trial at a research site in Chicago. Study-provided care at no cost to qualified participants.
Access ocular myasthenia gravis specialists in Chicago at no cost
This study follows strict safety protocols and ethical guidelines
All study-related ocular myasthenia gravis treatment provided free
The purpose of this study is to evaluate the efficacy and safety of efgartigimod PH20 SC given by a pre-filled syringe in adult patients with ocular myasthenia gravis. The study consists of a part A (approximately 7 weeks) and a part B (up to 2 years). In part A, half of the participants will receive efgartigimod PH20 SC and the other half will receive placebo. In part B, all participants will receive efgartigimod PH20 SC. The participants will be in the study for about up to 2 years and 12 week
Sponsor: argenx
Check if you qualify for this ocular myasthenia gravis clinical trial in Chicago, IL
If you're searching for ocular myasthenia gravis treatment options in Chicago, IL, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Chicago research site is actively enrolling participants for this clinical trial. You'll receive care from experienced ocular myasthenia gravis specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.